Skip to content
Partnerships

Partner with Allotar.

Allotar collaborates with pharmaceutical companies, research institutions, and strategic investors to accelerate the discovery and optimization of novel therapeutics.

Partnership highlights

Why Partner with Allotar

over 1000×

Less compute than enhanced sampling

Versus established workflows such as replica-exchange umbrella sampling applied to the same protein

90%

Allosteric site accuracy

Benchmarked across diverse protein families with interpretable AI

Modalities

Designed for the target site

Small molecules, macrocyclic peptides and computationally designed scaffolds

↻

Self-improving loop

Every outcome, hit or miss, sharpens the model and seeds the next cycle

Partnership opportunities

Partnering to Advance Precision Therapeutics

Allotar is an asset-driven discovery company advancing a focused pipeline through physics-based modeling and AI-guided design. We collaborate with pharmaceutical partners, biotech innovators, and investors to unlock high-value targets and accelerate the development of differentiated therapeutics.

Drug Discovery Partnerships

Apply AllotarX™ to priority targets using dynamics-driven modeling and selectivity-focused design to accelerate and de-risk discovery.

Pipeline Access & Licensing

Engage with internally developed programs at key inflection points for co-development, licensing, or strategic partnership.

Strategic Investment

Support the advancement of a scalable discovery platform and a growing pipeline targeting complex, underserved biology.

Contact

Start a Conversation

Tell us more about your partnership interests

Pittsburgh, PA & Austin, TX
contact@allotar.com

Your information is kept confidential. This form is protected by reCAPTCHA; the Google Privacy Policy and Terms of Service apply.

Explore the full scope of AllotarX™, across programs in neurodegeneration, rare disease and beyond.